Sanofi Logo

About mAIPC

Metastatic Androgen-Independent Prostate Cancer (mAIPC)

mAIPC is a rapidly progressing stage of prostate cancer. It leads to a marked deterioration in the quality of life, and most patients with prostate cancer die during this stage.1,2

There is a lack of consensus on the definition of mAIPC, but this stage may be characterized by confirmed metastases in the presence of castrate serum levels of testosterone (≤50 ng/mL) or rising PSA.3

Variable Manifestations of Metastatic Androgen-Independent Prostate Cancer (mAIPC)

Learn more about prostate cancer:


1. Scher HI, Leibel SA, Fuks Z, Cordon-Cardo C, Scardino PT. Cancer of the prostate. In: DeVita VT, Hellman S, Rosenberger SA, eds. Cancer: Principles & Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1192-1259. 2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-1597. 3. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone-refractory prostate cancer. Cancer Treat Rev. 2003;29(3):171-187.

Sanofi joins the fight against prostate cancer

ON THE LINE is a prostate cancer awareness campaign and Sanofi is co-sponsoring this initiative to help educate men and women about the importance of prostate screening. The campaign focuses on health education that harnesses the power of sports and celebrities to challenge men to take charge of their health. ON THE LINE offers educational materials for both men and women on prostate cancer, to promote a true "team" approach.

And Sanofi is fighting prostate cancer every way we can too. We know the stakes. Prostate cancer is the most commonly diagnose cancer in American men today. Every five minutes two more men are diagnosed with the disease. And it's the second leading cause of cancer death in the U.S.

From our earliest days, the goals of our cancer research have remained steadfast: to battle cancer with the most effective agents we can develop, to reduce the side effects of chemotherapy and to create breakthrough therapies for cancer patients. With the availability of new research techniques, we are also investigating targeted agents and novel approaches that may one day play an important role in advancing cancer management.

For more information about ON THE LINE, visit

Share the fight against prostate cancer.
Visit ON THE LINE on Facebook and YouTube

[Top of Page]